The investigation of the Effect of Melatonin Supplement on Dermatitis
Phase 3
- Conditions
- Dermatitis.
- Registration Number
- IRCT20220331054378N1
- Lead Sponsor
- Alborz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
12 year-old or older patients with dermatitis which has affected at least 5% of whole body
Signing the consent form by the patient.
Exclusion Criteria
Patients receiving systemic treatment for their dermatitis (exception: antihistamines).
Patients receiving sedatives.
Patients with history of allergic reactions to Melatonin or other ingredients in tablets.
If a patient refuses to continue the study at any time after the study started.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of dermatitis. Timepoint: Beginning and the end of the study. Method of measurement: SCORAD index.
- Secondary Outcome Measures
Name Time Method Quality of Sleep. Timepoint: Beginning and the end of the study. Method of measurement: ISI and ADSS index.;Quality of Life. Timepoint: Beginning and the end of the study. Method of measurement: DLQI index.;Severity of pain. Timepoint: Beginning and the end of the study. Method of measurement: NRS index.;Severity of itching. Timepoint: Beginning and the end of the study. Method of measurement: 12-PSS index.